Summary: Vitamin B12 supplementation does not directly cause joint pain, and no established causal link exists in medical literature
Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures
each 10% reduction in homocysteine is associated with 1.45-2.55 reduction in pulse pressure mmHg in patients undergoing hemodialysis (14)(27)(31) Increased urinary excretion of homocysteine in its sulfonated form (36) Omega-3 fatty acids 200-6,000 mg (~98-2,000 mg EPA/490-1,000 mg DHA) per day, for 1-12 months in patients with hyperhomocysteinemia or elevated homocysteine within normal ranges (8)(11)(13)(17)(18)(19)(25)(30)(42)(43) Reduced homocysteine by 1.18-1.58 mol/L on average using wide dose ranges, as shown in meta-analyses (8)(18) Reduced homocysteine by ~2.5-4.0 mol/L in patients with type II diabetes, patients on hemodialysis, or healthy adults using mid-range doses of 2,000-3,600 mg per day for 1-3 months and up to one year (11)(17)(25)(30)(42)(43) Reduced homocysteine by ~1.6 mol/L over 12 months in patients younger than 65 years, previously suffering from myocardial infarction (13) Adjunct therapy with folic acid, vitamin B6, and vitamin B12 improved efficacy (8)(17) Adjunct aerobic exercise and cognitive stimulation may be required for benefit in some populations, including older adults with mild cognitive impairment (19)
Each vial is sealed, lab-tested, and includes 0.9% benzyl alcohol to support extended usability after initial access
